

REFERENCES

- Abbud-Filho M, Adams PL, Alberu J :** A report of the Lisbon conference on the care of the kidney transplant recipient. *Transplantation*; 83:S1, 2007.
- Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, and Krieger M:** Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science* 271: 518–520, 1996.
- Ahsan N, Hricik D, Matas A :** Prednisone withdrawal in kidney transplant recipients and mycophenolate mofetil—a prospective randomized study. Steroid Withdrawal on cyclosporine Study Group. *Transplantation* 68:1865-1871, 1999.
- Allegra V, Martimbianco L, Vasile A:** Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet *Nephrol Dial Transplant*;12:924-932, 1997.
- Altmann SW, Davis HR , Zhu LJ :** Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. *Science*; 303:1201, 2004.
- Ando M, Sanaka T, Nihei H:** Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. *J Am Soc Nephrol* 10: 2177–2184, 1999.
- Andreucci VE, Fissell RB, Bragg-Gresham JL:** Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. *Am J Kidney Dis* 44:61–7, 2004.
- Angeles C, Lane BP, Miller F, Nord EP :** Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. *Am J Kidney Dis*; 44:543, 2004.
- Antonio C:** Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. *Curr Opin Lipidol.* 17:510–518, 2006.
- Arnadottir M:** Pathogenesis of dyslipoproteinemia in renal insufficiency: The role of lipoprotein lipase and hepatic lipase. *Scand J Clin Lab Invest* 57: 1–11, 1997.

- Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Blom HJ, Sweep FC, Demacker PN, Hilbrands LB:** Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. *J Am Soc Nephrol*;14:1880-1888, 2003.
- Asselbergs FW, Diercks GF, Hillege HL:** Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. *Circulation* 110:2809–16, 2004.
- Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M:** The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. *J Clin Pathol* 57: 728–734, 2004.
- Attman PO, Alaupovic P:** Lipid and apolipoprotein profiles of uremic dyslipoproteinemia: Relation to renal function and dialysis. *Nephron* 57: 401–410, 1991.
- Attman PO, Alaupovic P, Tavella M, Knight- Gibson C:** Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. *Nephrol Dial Transplant*. 11:63-69, 1996.
- Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, Knight-Gibson C, Alaupovic P:** Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. *Kidney Int* 55:1536-1542, 1999.
- Bachorik PS, Cloey TA, Finney CA :** Lipoprotein-cholesterol analysis during screening: Accuracy and reliability. *Ann Intern Med* 114:741,1991.
- Baigent C, Landry M:** Study of Heart and Renal Protection (SHARP). *Kidney Int* 63 Suppl:S207–10, 2003.

- Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, Cairns HS, Collins R, Foley RN, Frighi V, Kourellias K, Ratcliffe PJ, Rogerson M, Scoble JE, Tomson CRV, Warwick G, Wheeler DC:** First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. *Am J Kidney Dis* 45: 473–484, 2005.
- Bakker-Arkema RG, Davidson MH, Goldstein RJ :** Efficacy and safety of a new HMG CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. *JAMA* 276:128, 1996.
- Batista MC, Welty FK, Diffenderfer MR, Sarnak MJ, Schaefer EJ, Lamon-Fava S, Asztalos BF, Dolnikowski GG, Brousseau ME, Marsh JB:** Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. *Metabolism* 53: 1255– 1261, 2004.
- Baye B , Pastor MC , Bonal J , Junca J , Hernandez JM , Riutort N ,Foraster A, Romero R:** Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. *Nephrol Dial Transplant* 18: 106–112, 2003.
- Bays HE:** Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. *Am J Cardiol* 98:71–76, 2006.
- Bays HE:** Safety considerations with omega-3 fatty acid therapy. *Am J Cardiol* 99:35C–43C, 2007.
- Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A:** Nonlipid- related effects of statins. *Ann Med* 32: 164–176, 2000.
- Berg AL, Nilsson-Ehle P :** ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. *Kidney Int*; 50:538, 1996.
- Bianchi S, Bigazzi R, Caiazza A, Campese VM:** A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. *Am J Kidney Dis* 41: 565–570, 2003.
- Bleyer AJ, Garrett B, Kant KS, Lynch D, Rahman N, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky :** An open-label, cross-over study of the new phosphate binder RenaGel in the management of hyperphosphatemia in ESRD patients. *Am J Kidney Dis* 33: 694-701, 1999.

- Blum CB:** Comparison of properties of four inhibitors of 3-hydroxy- 3-methylglutaryl-coenzyme a reductase. *Am J Cardiol* 73:3D-11D, 1994.
- Boaz M, Smetana S, Weinstein T, Matas Z, Gafer U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS:** Secondary Prevention with Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): Randomised placebo-controlled trial. *Lancet* 356: 1213–1218, 2000.
- Boes E, Fliser D, Ritz E, Konig P, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Riegler P, Kronenberg F:** Apolipoprotein A-IV predicts progression of chronic kidney disease: The mild to moderate kidney disease study. *J Am Soc Nephrol* 17: 528–536, 2006.
- Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T, Kirilov G:** Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis. *Nephrol Dial Transplant*;8:93, 1993.
- Bosch T, Gahr S, Belschner U, Schaefer C, Lennertz A, Rammo J:** Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: Results of a prospective long-term multicenter follow-up covering 12,291 sessions. *Ther Apher Dial* 10: 210–218, 2006.
- Brewer BH:** Increasing HDL cholesterol levels. *N Engl J Med* 350:1491, 2004.
- Broeders, N, Tielemans C, Abramowicz D:** Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? *Nephrol Dial Transplant* 15:1993-1999, 2000.
- Brown AS, Bakker-Arkema RG, Yellen L :** Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. *J Am Coll Cardiol* 32:665, 1998.
- Brown MS, Goldstein JL :** A receptor-mediated pathway for cholesterol homeostasis. *Science* 232:34, 1986.

- Brown JH, Murphy BG, Douglas AF** :Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. *Nephron*; 75:277, 1997.
- Brown WV**: Expert commentary: the safety of fibrates in lipid-lowering therapy. *Am J Cardiol*;99:19C-21C, 2007.
- Buchanan C, Smith L, Corbett J** : A retrospective analysis of ezetimibe treatment in renal transplant recipients. *Am J Transplant*; 6:770, 2006.
- Buhman KK, Accad M, Novak S**: Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. *Nat Med* 6:1341, 2000.
- Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T**: Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. *J Am Soc Nephrol*. 16:1936 –1947,2005.
- Campese VM, Nadim MK, Epstein M**: Are 3 hydroxy3- methylglutaryl CoA reductase inhibitors renoprotective? *J Am Soc Nephrol*. 16: S11–S17, 2005.
- Carlson LA, Hamsten A, Asplund A**: Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. *J Intern Med* 226: 271–276, 1989.
- Carr AC, Myzak MC, Stocker R, HeineckeJW**: Myeloperoxidase binds to low-density lipoprotein: Potential implications for atherosclerosis. *FEBS Lett* 487:176–180, 2000.
- Chapman MJ**:Pharmacology of fenofibrate. *Am J Med* 83:21–5, 1987.
- Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA**: Differential interaction of 3-hydroxy-3-methylglutaryl- CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. *Drug Metab Dispos* 33: 537–546, 2005.
- Chertow GM, Burke SK, Dilion MA** : Long-term effects of sevelamer hydrochloride on the calcium X phosphate product and lipid profile of hemodialysis patients. *Nephrol Dial Transplant* 14:2907–2914, 1999.

- Chertow GM, Burke SK, Raggi P** : Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 62:245–252, 2002.
- Chmielewski M, Bryl E, Marzec L, Aleksandrowicz E, Witkowski JM, Rutkowski B**: Expression of scavenger receptor CD36 in chronic renal failure patients. *Artificial Organs*. 29:608–614, 2005.
- Chmielewski M , Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P**: Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. *J NEPHROL* 21: 635-644, 2008.
- Choy JC, Granville DJ, Hunt DW** : Endothelial cell apoptosis: Biochemical characteristics and potential implications for atherosclerosis. *J Mol Cell Cardiol* 33:1673–1690, 2001.
- Cofan F, Gilabert R, Zambon D** : Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients. *Transplant Proc*; 34:384, 2002.
- Cohn JS, McNamara JR, Cohn SD** : Postprandial plasma lipoprotein changes in human subjects of different ages. *J Lipid Res*; 29:469,1988.
- Cooper GR, Myers GL, Smith SJ, Schlant RC** : Blood lipid measurements. Variations and practical utility. *JAMA*; 267:1652,1992.
- Corsini A, Holdass H**: Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. *Ren Fail* 27:259 –73, 2005.
- Cromwell WC, Otvos JD** : Low-density lipoprotein particle number and risk for cardiovascular disease. *Curr Atheroscler Rep* 6:381,2004.
- Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL**: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. *Arch Intern Med* 161: 1413–1419, 2001.

- Danesh J, Collins R, Peto R:** Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. *Circulation* 102: 1082–1085, 2000.
- Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, Leroux-Robert C:** Decrease of serum paraoxonase activity in chronic renal failure. *J Am Soc Nephrol* 9: 2082–2088, 1998.
- Dasgupta A, Kenny MA, Ahmad S:** Abnormal fatty acid profile in chronic hemodialysis patients: Possible deficiency of essential fatty acids. *Clin Physiol Biochem* 8: 238– 243, 1990.
- Davidson MH, McKenney J, Stein E:** for the Atorvastatin Study Group I. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. *Am J Cardiol* 79:1475, 1997.
- Davidson MH, Armani A, McKenney JM, Jacobson TA:** Safety considerations with fibrate therapy. *Am J Cardiol* 99:3C–18C, 2007.
- Davignon J, Gregg RE, Sing CF:** Apolipoprotein E polymorphism and atherosclerosis. *Arteriosclerosis* 8:1, 1988.
- Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ:** The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remanants in nephrotic range proteinuria. *Atherosclerosis*; 157:211-220,2001.
- Deleuze S, Garrigue V, Delmas S, Chong G, Swarcz I, Cristol JP, Mourad G:** New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine? *Transplant Proc* ;38:2311-2313, 2006.
- Demant T, Mathes C, Gutlich K, Bedynek A, Steinhauer HB, Bosch T, Packard CJ, Warwick GL:** A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. *Kidney Int*; 54:2064-2080, 1998.
- Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T:** Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. *Am J Kidney Dis* 45:39-47, 2005.

- Desmeules S, Arcand-Bosse JF, Bergeron J, Douville P, Agharazii M:** Nonfasting nonhigh-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. *Am J Kidney Dis* 45:1067–72, 2005.
- Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP:** HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 23:58–63, 2003.
- Diepeveen SH, Verhoeven GW, Van Der Palen J, Dikkeschei LD, Van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF:** Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: A randomised-controlled trial. *J Intern Med* 257: 438–445, 2005.
- Diepeveen SH, Wetzels JF , Bilo HJ , van Tits LJ , Stalenhoef AF:** Cholesterol in end-stage renal disease. *J Medicine* 66 (2):53-61, 2008.
- Dieplinger H, Kronenberg F:** Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1). *Wien Klin Wochenschr* 111: 5–20, 1999.
- Dierkes J, Westphal S, Luley C:** The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. *Expert Opin Drug Saf* 3:101–11, 2004.
- Diskin CJ, Thomas CE, Zellner CP, Lock S, Tanja J:** Fish oil to prevent intimal hyperplasia and access thrombosis. *Nephron* 55: 445–447, 1990.
- Dobell E, Chan M, Williams P, Allman M:** Food preferences and food habits of patients with chronic renal failure undergoing dialysis. *J Am Diet Assoc* 93: 1129–1135, 1993.
- Donnelly SM, Ali MA, Churchill DN:** Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. *J Am Soc Nephrol* 2: 1634–1639, 1992.
- Douglas K, O'Malley PG, Jackson JL:** Meta-analysis: the effect of statins on albuminuria. *Ann Intern Med*. 145:117–124, 2006.

- Ehara S, Ueda M, Naruko T** : Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. *Circulation* 103: 1955–1960, 2001.
- Elisof M, Mikhailidis DP, Siampoulos KC**: Dyslipidemia in patients with renal disease. *J Drug Dev Clin Pract* 17: 331–348, 1996
- Esterbauer H, Puhl H, Waeg G, Krebs A, Tatzber F, Rabol H**: Vitamin E and atherosclerosis-an overview. *Japan Sci Soc Press* 233-41, 1993.
- Evans JR, Forland SC, Cutler RE**: The effect of renal function on the pharmacokinetics of gemfibrozil. *J Clin Pharmacol* 27:994–1000,1997.
- Faas FH, Earleywine A, Smith G, Simmons DL** : How should low-density lipoprotein cholesterol concentration be determined?. *J Fam Pract*; 51:972,2002.
- Fazio S, Linton MF**: Apolipoprotein AI as therapy for atherosclerosis: Does the future of preventive cardiology include weekly injections of the HDL protein? *Mol Interv* 3: 436–440, 2003.
- Fellström BC, Holdaas H, Jardine AG**: Why do we need a statin trial in hemodialysis patients? *Kidney Int* 63 Suppl:S204–6, 2003.
- Fellström BC, Holdaas H, Jardine AG** : Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. *Kidney Int*; 66:1549, 2004.
- Fellström BC, Holdaas H, Jardine AG, Schmieder RE** : for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med*. 360:1395-1407, 2009.
- Fielding CJ and Fielding PE** : Cellular cholesterol efflux. *Biochim Biophys Acta* 1533: 175–189, 2001.
- Foley RN, Parfrey PS, Sarnak MJ**: Epidemiology of cardiovascular disease in chronic renal disease. *J Am Soc Nephrol* 9:S16-23, 1998.

- Fried LF, Orchard TJ, Kasiske BL:** for the Lipids and Renal Disease Progression Meta-Analysis Study Group: Effect of lipid reduction on the progression of renal disease: A metaanalysis. *Kidney Int* 59: 260–269, 2001.
- Friedewald WT, Levy RI, Fredrickson DS :** Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*; 18:499,1972.
- Friedman A, Moe S:**Review of the Effects of Omega-3 Supplementation in Dialysis Patients. *Clin J Am Soc Nephrol* 1: 182–192, 2006.
- Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, Koenig P, Ikewaki K, Dieplinger H:** In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. *Kidney Int* 71: 1036–1043, 2007.
- Fruchart JC, Brewer HB, Leitersdorf E :** Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. *Am J Cardiol*; 81:912,1998.
- Gehr TWB, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF:** The pharmacokinetics of pravastatin in patients on chronic hemodialysis. *Eur J Clin Pharmacol*. 53:117–121, 1997.
- Ginsberg HN:** Lipoprotein metabolism and its relation to atherosclerosis. *American Journal of Medicine* 80:7-11,1994.
- Ginsberg HN, Le NA, Goldberg IS :** Apolipoprotein metabolism in subjects with deficiency of apolipoproteins CIII and AI: Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. *J Clin Invest* 78:1287, 1986.
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY:** Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 351:1296-1305, 2004.
- Goldsmith D, Ritz E, Covic A:** Vascular calcification: A stiff challenge for the nephrologists. Does preventing bone disease cause arterial disease? *Kidney Int* 66:1315–1333, 2004

- Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC:** Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. *Kidney Int* ;66:753-760, 2004.
- Grandaliano G, Biswas P, Choudhury GG, Abboud HE:** Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. *Kidney Int.* 44:503–508, 1993.
- Groth CG, Backman L, Morales JM:** Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. *Transplantation* 67:1036-42 ,1999.
- Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT:** National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation.* 13;110:227– 239, 2004.
- Guijarro C, Egido J:** Transcription factor-B (NF- κ B) and renal disease. *Kidney Int.* 59:415– 424, 2001.
- Guyard-Dangremont V, Lagrost L, Gamber P:** Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. *J Lipid Res* 35: 982–992, 1994.
- Habibi J, Whaley-Connell A, Qazi MA, Hayden MR, Cooper SA:** Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. *Endocrinology.* 148:2181–2188, 2007.
- Harpel PC, Gordon BR, Parker TS:** Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. *Proc Natl Acad Sci U S A* 86: 3847–3851, 1989.
- Harper CR, Jacobson TA:** Treatment of Dyslipidemia in CKD. *JACC* 51 (25) :2375–84, 2008.
- Harris KP, Wheeler DC, Chong CC:** A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. *Kidney Int.* 61:1469–74, 2002.

- Hazell LJ, Van Den Berg JJM, Stocker R:** Oxidation of low- density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. *Biochem J* 302:297–304, 1994.
- Hervio L, Girard-Globa A, Durlach V, Angles-Cano E:** The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. *Eur J Clin Invest* 26: 411–417, 1996
- Herzog CA, Ma JZ, Collins AJ:** Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. *N Engl J Med* 339:799-805, 1998.
- Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA:** The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. *J Am Soc Nephrol*;5:2073-2081, 1995.
- Hirsch D, Azoury R, Sarig S, Kruth HS:** Colocalization of cholesterol and hydroxyapatite in human atherosclerotic lesions. *Calcif Tissue Int* 52:94–98, 1993.
- Holdaas H, Fellstrom B, Cole E :** Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. *Am J Transplant*; 5:2929, 2005.
- Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P:** for the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet* 361:2024-31, 2003.
- Holdaas, H, Fellstrom B, Jardine AG :** Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. *Nephrol Dial Transplant*; 20:974, 2005.
- Hoogeveen RC, Ballantyne CM, Pownall HJ:** Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. *Transplantation*. 72:1244-50, 2001.

- Horkko S, Huttunen K, Kervinen K :** Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. *Eur J Clin Invest* 24:105–113, 1994.
- Hottelart C, El Esper N, Achard JM, Pruna A, Fournier A:** Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. *Nephrologie* 20:41–4, 1999.
- Hricik DE, Whalen CC, Lautman J:** The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. *Transplantation* 54:868, 1992.
- Hufnagel G, Michel C, Vrtovsni F, Queffeulou G, Kossari N, Mignon F:** Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. *Nephrol Dial Transplant.*;15:684–8, 2000.
- Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H:** Delayed in vivo catabolism of intermediate-density lipoprotein and lowdensity lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. *Arterioscler Thromb Vasc Biol* 25: 2615–2622, 2005.
- Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J:** Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. *Clin Nephrol* 58: 190–197, 2002.
- Inoue CN, Nagano I, Ichinohasama R :** Bimodal effects of platelet-derived growth factor on rat mesangial cell proliferation and death, and the role of lysophosphatidic acid in cell survival. *Clin Sci (Lond)* 101:11–19, 2001.
- Iseki K, Yamazato M, Tozawa M, Takishita S:** Hypcholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. *Kidney Int* 61: 1887–1893, 2002.
- Islam KN, O’Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I:** Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. *Atherosclerosis* 150: 217–224, 2000.

- Istvan ES, Deisenhofer J** : Structural mechanism for statin inhibition of HMG-CoA reductase. *Science* 292:1160, 2001.
- Jacobson TA, Armani A, McKenney JM, Guyton JR**: Safety considerations with gastrointestinally active lipid-lowering drugs. *Am J Cardiol* 99:47C–55C, 2007.
- Jacobson TA, Zimmerman FH**: Fibrates in combination with statins in the management of dyslipidemia. *J Clin Hypertens* 8:35– 41, 2006.
- Jaconello P**: Niacin versus niacinamide". *CMAJ* 147 (7): 990, 1992.
- Jardine AG, Holdaas H, Fellstrom B** : Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: Post-Hoc subgroup analyses of the ALERT study. *Am J Transplant*; 4:988, 2004.
- Jin F-Y, Kamanna VS, Chuang M-Y** : Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). *Arterioscler Thromb Vasc Biol* 16:1052, 1996.
- Johnson BA, Iacono AT, Zeevi A** : Statin use is associated with improved function and survival of lung allografts. *Am J Respir Crit Care Med*; 167:1271, 2003.
- Jones PH, Davidson MH, Stein EA** : Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). *Am J Cardiol* 92:152, 2003.
- Kaiser S, Di MP, Murphy ME, Sies H**: Physical and chemical scavenging of singlet molecular oxygen by tocopherols. *Arch Biochem Biophys* 277:101-8, 1990.
- Kalantar-Zadeh K, Kovesdy C, Derosé S, Horwich T, Fonarow G**: Racial and survival paradoxes in chronic kidney disease. www.nature.com/clinical practice/neph 3(9): 493-506, 2007.
- Kaneda H, Taguchi J, Ogasawara K**: Increased level of advanced oxidation protein products in patients with coronary artery disease. *Atherosclerosis* 162:221–225, 2002.

- Kasiske B, Cosio FG, Beto J :** Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. *Am J Transplant*; 4 Suppl 7:13, 2004.
- Kastelein JJ, Isaacsohn JL, Ose L :** Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. *Am J Cardiol* 86:221, 2000.
- Katopodis KP, Andrikos EK, Gouva CD, Bairaktari ET, Nikolopoulos PM, Takouli LK, Tzallas CS, Elisaf MS, Pappas MV, Siamopoulos KC:** Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. *Perit Dial Int*;26:320-327, 2006.
- Kawagishi T, Nishizawa Y, Konishi T:** High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. *Kidney Int* 48:820–826, 1995.
- Kaysen GA:** The microinflammatory state in uremia: causes and potential consequences. *J Am Soc Nephrol*. 12:1549-1557, 2001.
- Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW:** The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients: the HEMO Study Group. *Kidney Int*. 58: 346-352, 2000.
- Keech A, Simes RJ, Barter P:** Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [see comment]. *Lancet* 366:1849–61, 2005.
- Kerschdorfer L, Konig P, Neyer U, Bosmuller C, Lhotta K, Auinger M, Hohenegger M, Riegler P, Margreiter R, Utermann G, Dieplinger H, Kronenberg F:** Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. *Atherosclerosis*;144:381-391, 1999.
- Kimak E, Soliski J, Baranowicz-Gaszczyk I, Ksiazek A:** A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients. *Ren Fail*;28:483-486, 2006.

- Knauf H, Kolle EU, Mutschler E:** Gemfibrozil absorption and elimination in kidney and liver disease. *Klin Wochenschr* 68:692–8, 1990.
- Knopp RH, Alagona P, Davidson M, Goldberg AC :** Equivalent efficacy of a time-release form of niacin (Niaspan®) given once-a-night vs. plain niacin in the management of hypertriglyceridemia. *Metabolism*; 47:1097, 1998.
- Kobashigawa JA, Katznelson S, Laks H:** Effect of pravastatin on outcomes after cardiac transplantation. *N Engl J Med* 333:621-627, 1995.
- Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F:** Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. *J Am Soc Nephrol* 8: 1889–1898, 1997.
- Kohnle M, Pietruck, F, Kribben, A :** Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. *Am J Transplant* 6:205, 2006.
- Kohnle M, Zimmermann U, Lutkes P:** Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia. *Transpl Int* 13 Suppl 1:S345,2000.
- Koorts AM, Viljoen M, Kruger MC:** Red blood cell fatty acid profile of chronic renal failure patients receiving maintenance haemodialysis treatment. *Prostaglandins Leukot Essent Fatty Acids* 67: 13–18, 2002.
- Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ:** Supratherapeutic response to ezetimibe administered with cyclosporine. *Ann Pharmacother* 39: 1561–1565, 2005.
- Kraemer FB, Takeda D, Natsu V :** Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways. *Metabolism* 47:555-559, 1998.
- Kramer BK, Montagnino G, Del Castillo D :** Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. *Nephrol Dial Transplant*; 20:968, 2005.

- Kraus LM, Kraus AP:** Carbamylation of amino acids and proteins in uremia. *Kidney Int* 78:S102–S107, 2001.
- Kreis H, Cisterne JM, Land W:** Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. *Transplantation* 69: 1252–1260, 2000.
- Krentz AJ:** Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. *Diabetes Obes Metab* 5[Suppl 1]: S19–S27, 2003.
- Kronenberg F:** Dyslipidemia and nephrotic syndrome: Recent advances. *J Ren Nutr* 15: 195–203, 2005.
- Kronenberg F, König P, Neyer U, Auinger M, Pribasnik A, Lang U, Reiterer J, Pinter G, Utermann G, Dieplinger H:** Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. *J Am Soc Nephrol* 6: 110–120, 1995.
- Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J:** Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study. *Circulation* 100: 1154–1160, 1999.
- Kronenberg F, Kuen E, Ritz E, König P, Kraatz G, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Riegler P, Schwenger V, Von Eckardstein A:** Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. *J Am Soc Nephrol* 13: 461–469, 2002.
- Kronenberg F, Lhotta K, König P, Margreiter R, Dieplinger H, Utermann G:** Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation. *Eur J Hum Genet* 11: 693–699, 2003.
- Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, König P, Thiery J, Koch M, von Eckardstein A, Dieplinger H:** The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. *Kidney Int* 65: 606–612, 2004.

- Kuldo JM, Ogawara KI, Werner N, Asgeirsdóttir SA, Kamps JA, Kok RJ, Molema G:** Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. *Curr Vasc Pharmacol.* 3:11–39, 2005.
- Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, Amann FW:** Relation of cyclosporine blood levels to adverse effects on lipoproteins *Transplantation*;57:1479-1483, 1994.
- Kwan B, Kronenberg F, Beddhu S, Cheung AK:** Lipoprotein metabolism and lipid management in chronic kidney disease. *J Am Soc Nephrol* 18: 1246–1261, 2007.
- Lal SM, Hewett JE, Petroski GF :** Effects of nicotinic acid and lovastatin in renal transplant recipients: a prospective, randomized, open-labeled crossover trial. *Am J Kidney Dis*; 25:616, 1995.
- Landray M, Baigent C, Leaper C:** The second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. *Am J Kidney Dis* 47:385–95, 2006.
- LaRosa JC, He J, Vupputuri S :** Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. *Jama*; 282:2340, 1999.
- Launay-Vacher V, Izzedine H, Deray G:** Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. *Int J Cardiol* 101: 9–17, 2005.
- Leary ET, Wang T, Baker DJ, Cilla DD, Zhong J, Warnick GR, Nakajima K, Havel RJ:** Evaluation of an immunoseparation method for quantitative measurement of remnantlike particle-cholesterol in serum and plasma. *Clin Chem* 44: 2490–2498, 1998
- Lee TM, Su SF, Tsai CH:** Effect of pravastatin on proteinuria in patients with well-controlled hypertension. *Hypertension* 40: 67–73, 2002.

- Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, Heinecke JW:** Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. *J Biol Chem* 272:3520–3526, 1997.
- Liang K and Vaziri ND.** Gene expression of LDL receptor, HMG-CoA reductase and cholesterol-7 α -hydroxylase in chronic renal failure. *Nephro Dial Transplant* 12: 1381–1386, 1997.
- Lingenhel A, Lhotka K, Neyer U, Heid IM, Rantner B, Kronenberg MF, König P, von Eckardstein A, Schober M, Dieplinger H, Kronenberg F:** Role of the kidney in the metabolism of apolipoprotein A-IV: Influence of the type of proteinuria. *J Lipid Res* 47: 2071–2079, 2006.
- Littlewood TD, Bennett MR:** Apoptotic cell death in atherosclerosis. *Curr Opin Lipidol* 14: 469–475, 2003
- Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ:** Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. *JAMA* 291: 451–459, 2004.
- Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR, Fink NE, Levey AS, Coresh J:** High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. *J Am Soc Nephrol* 16: 1794–1802, 2005.
- Longenecker JC, Klag MJ, Marcovina SM, Powe NR, Fink NE, Giaculli F, Coresh J:** Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE Study. *Circulation* 106: 2812–2818, 2003.
- Lowrie EG:** Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. *Am J Kidney Dis.* 32(6 suppl 4):S105-S112, 1998.
- Lowrie EG, Lew NL:** Commonly measured laboratory variables in hemodialysis patients: Relationships among them and to death risk. *Semin Nephrol* 12: 276–283, 1992.

- Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G:** Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? *Kidney Int* 45: 876–883, 1994.
- Malle E, Waeg G, Schreiber R:** Immunological evidence for the myeloperoxidase/H₂O₂/halide system in human atherosclerotic lesions: Colocalization of myeloperoxidase and hypochlorite-modified proteins. *Eur J Biochem* 267:4495–4503, 2000.
- Mann JF, Lonn EM, Yi Q:** Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. *Kidney Int* 65:1375-80, 2004.
- Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP:** Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). *Clin Chem* 41: 246–255, 1995.
- Marcovina SM, Koschinsky ML:** Lipoprotein(a) as a risk factor for coronary artery disease. *Am J Cardiol* 82: 57U– 66U, 1998.
- Marsche G, Hammer A, Oskolkova O :** Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. *J Biol Chem* 277:32172–32179, 2002.
- Marz W, Scharnagl H, Abletshauser C:** Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. *Circulation* 103:1942, 2001.
- Mason PR, Walter MF, Jacob RF:** Effects of HMG- CoA reductase inhibitors on Endothelial function. *Circulation*. 109:II-34 –II-41,2004.
- Masterson R, Hewitson T, Leikis M :** Impact of statin treatment on 1-year functional and histologic renal allograft outcome. *Transplantation*; 80:332, 2005.

- Maugeais C, Braschi S, Ouguerram K, Maugeais P, Mahot P, Jacotot B, Darmaun D, Magot T, Krempf M:** Lipoprotein kinetics in patients with analbuminemia. Evidence for the role of serum albumin in controlling lipoprotein metabolism. *Arterioscler Thromb Vasc Biol* ; 17:1369-1375, 1997.
- McCullough PA, Brown WW, McGill JB, Collins AJ, Chen SC:** for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk factor; results from the Kidney Early Evaluation Program (KEEP). *J Am Coll Cardiol* 45:424A, 2005.
- McCullough PA, Rocher LR, Nistala R , Whaley-Connell A :** Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins. *Journal of Clinical Lipidology* 2 : 318–327, 2008.
- McFarlane SI, Muniyappa R, Francisco R, Sowers JR:** Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. *J Clin Endocrinol Metab.* 87:1451–1458, 2002.
- McKenzie IF, Nestel PJ:** Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome. *J Clin Invest*; 47:1685-1695, 1968.
- Memon RA, Staprans I, Noor M :** Infection and inflammation induce LDL oxidation in vivo. *Arterioscler Thromb Vasc Biol* 20: 1536–1542, 2000.
- Mezzano D, Pais EO, Aranda E;** Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. *Kidney Int* 60: 1844–1850, 2001.
- Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P:** Alterations in lipoprotein composition in peritoneal dialysis patients. *Perit Dial Int* 22: 220–228, 2002
- Molitch MF :** Management of dyslipidemias in patients with diabetes and chronic kidney disease. *Clin J Am Soc Nephrol*;1:1090-1099, 2006.
- Moore KJ, Freeman MW:** Scavenger receptors in atherosclerosis: Beyond lipid uptake. *Arterioscler Thromb Vasc Biol* 26: 1702–1711, 2006.

- Moorhead JF, Brunton C, Fernando RL, Burns A, Varghese Z:** Do glomerular atherosclerosis and lipid-mediated tubulo-interstitial disease cause progressive renal failure in man? *Blood Purif*;14:58-66,1996.
- Morimoto H, Nakao K, Fukuoka K:** Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. *Nephrol Dial Transplant* 20:2775-82, 2005.
- Mune M, Yukawa S, Kishino M, Otani H, Kimura K, Nishikawa O, Takahashi T, Kodama N, Saika Y, Yamada Y:** Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. *Kidney Int Suppl* 71: S126–S129, 1999.
- Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ:** Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. *Kidney Int*; 58:293–301,2000 .
- National Cholesterol Education Program (NCEP):** Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 285:2486–2497, 2001.
- National Kidney Foundation.** K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. *Am J Kidney Dis*. 41(suppl 3):S1–S92, 2003.
- Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, and Fogelman AM :** HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. *Arterioscler Thromb Vasc Biol* 21: 481–488, 2001.
- Navab M, Hama SY, Reddy ST, Ng CJ, Van Lenten BJ, Laks H, Fogelman AM:** Oxidized lipids as mediators of coronary heart disease. *Curr Opin Lipidol* 13: 363–372, 2002
- Neuvonen PJ, Niemi M, Backman JT:** Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance, *Clin Pharmacol Ther*:80:565-581, 2006.

- Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, Ishimura E, Nakatani T, Miki T, Inaba M:** Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. *Kidney International* 63 (84): 117–120, 2003.
- Nishizawa Y, Shoji T, Kawagishi T, Morii H:** Atherosclerotic lesions in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. *Kidney Int Suppl* 62: S90-S92, 1997.
- Nogueira J, Weir M:** The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. *Clin J Am Soc Nephrol* 2: 766–785, 2007.
- O-hara M, Esato K, Harada M, Kouchi Y, Akimoto F, Nakamura T, Wakamatsu T, Zempo N:** Eicosapentanoic acid suppresses intimal hyperplasia after expanded polytetrafluoroethylene grafting in rabbits fed a high cholesterol diet. *J Vasc Surg* 13: 480–486, 1991.
- Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T:** Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. *Kidney Int Suppl* 71: S227–S228, 1999.
- Ok E , Basnakian AG, Apostolov EO , Barri YM, Shah SV:** Carbamylated low-density lipoprotein induces death of endothelial cells: A link to atherosclerosis in patients with kidney disease. *Kidney International* 68: 173–178, 2005
- Ozsoy RC, van Leuven SI, Kastelein JJ, Arisz L, Koopman MG:** The dyslipidemia of chronic renal disease: effects of statin therapy. *Curr Opin Lipidol* 17:659–666, . 2006.
- Palabrica TM, Liu AC, Aronovitz MJ:** Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistance to tissue plasminogen activator-mediated thrombolysis. *Nat Med* 1:256, 1995.
- Pandak WM, Vlahcevic ZR, Heuman DM, Krieg RJ, Hanna JD, Chan JC.** Post-transcriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7 α -hydroxylase in rats with subtotal nephrectomy. *Kidney Int* 46: 358–364, 1994.

- Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD:** PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. *Nephrol Dial Transplant*;21:1270-1277, 2006.
- Parfrey PS, Foley RN:** The clinical epidemiology of cardiac disease in chronic renal failure. *J Am Soc Nephrol* 10:1606-151999.
- Pascual M, Curtis J, Delmonico FL :** A prospective randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. *Transplantation* 75: 1501, 2003.
- Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C:** ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *Stroke* 33: 2337–2341,2002.
- Peck LW, Monsen ER, Ahmad S:** Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. *Am J Clin Nutr* 64: 210–214, 1996.
- Pecoits-Filho R, Lindholm B, Stenvinkel P:** The malnutrition, inflammation, and atherosclerosis (MIA) syndrome *Nephrol Dial Transplant*. 17(suppl 11): 28-31, 2002.
- Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR:** Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. *N Engl J Med* 312: 1210–1216, 1985.
- Podder H, Slepkowski SM, Napoli KL, et al:** Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. *J Am Soc Nephrol*;12:I059-1071, 2001.
- Pollock CA, Wyndham R, Collett PV, Elder G, Field MJ, Kalowski S, Lawrence JR, Waugh DA, George CR:** Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. *Kidney Int*;45:897-902, 1994.
- Prata MM, Madeira C, Vicente O, Miguel MJ:** Lipid profile in haemodialysis patients treated with recombinant human erythropoietin. *Nephrol Dial Transplant*;13:2345-2347, 1998 .

- Prichard S:** Coronary artery disease in end-stage renal disease: Risk factors and treatment strategies. *J Jpn Soc Dial Ther* 33: 159–164, 2000.
- Prichard S:** Impact of Dyslipidemia in End-Stage Renal Disease. *J Am Soc Nephrol* 14: S315–S320, 2003.
- Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH:** Effects of fibrates on metabolism of statins in human hepatocytes. *Drug Metab Dispos* 30:1280–7, 2002.
- Puthenparumpil JJ, Keough-Ryan T, Kiberd M :** Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. *Transplant Proc* 37:1033, 2005.
- Quaschnig T, Krane V, Metzger T, Wanner C:** Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. *Am J Kidney Dis* 38:S14-9, 2001.
- Quaschnig T, Mainka T, Nauck M, Rump LC, Wanner C, Kramer-Guth A:** Immunosuppression enhances atherogenicity of lipid profile after transplantation. *Kidney Int Suppl*;71:S235-S237, 1999.
- Quérin S, Lambert R, Cusson JR:** Single-dose pharmacokinetics of ¹⁴C-lovastatin in chronic renal failure. *Clin Pharmacol Ther.* 50:437– 441, 1991.
- Qunibi WY:** Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). *Kidney International* 67 (95) : S43–S50, 2005.
- Raabe M, Veniant MM, Sullivan MA:** Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. *J Clin Invest* 103:1287, 1999.
- Rader DJ, Hoeg JM, Brewer HB :** Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. *Ann Intern Med* 120:1012, 1994.
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH:** Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 336: 973–979, 1997.

- Ridker PM, Danielson E, Fonseca FA** : Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 359: 2195- 2207, 2008 .
- Ridker PM, Ilenckens CH, Buring IE, Rifai N**: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med*;342:836-843, 2000.
- Rip J, Nierman MC, Sierts JA, Petersen W, Van den Oever K, Van Raalte D, Ross CJ, Hayden MR, Bakker AC, Dijkhuizen P, Hermens WT, Twisk J, Stroes E, Kastelein JJ, Kuivenhoven JA, Meulenberg JM**: Gene therapy for lipoprotein lipase deficiency: Working toward clinical application. *Hum Gene Ther* 16: 1276–1286, 2005.
- Ritz E, Wanner C**: Lipid Changes and Statins in Chronic Renal Insufficiency. *J Am Soc Nephrol* 17: S226–S230, 2006.
- Rodandi KM**: Hyperlipidemia, in Herfindal ET, Gourley DR (eds):textbook of Therapeutics: Drug and Disease Management. Baltimore,Wiiliams&Wilkins: 387-403,1996.
- Rosenson RS** : Rosuvastatin , a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. *Expert Rev Cardiovasc Ther* 1:495, 2003.
- Rosenson RS** : Clinical role of LDL and HDL subclasses and apolipoprotein measurement. *ACC Curr J Rev*; 13:33,2004.
- Rosenson RS, Lloyd-Jones D** : A critical appraisal of revised cholesterol guidelines for the very high-risk patient. *Expert Rev Cardiovasc Ther*; 3:173,2005.
- Rovin BH, Tan LC**: LDL stimulates mesangial fibronectin production and chemoattractant expression. *Kidney Int*. 43:218 –225, 1993.
- Rubenfire M, Coletti AT, Mosca L**: Treatment Strategies for Management of Serum Lipids. *Progress in Cardiovascular Diseases* 41:95-116,1998.
- Sahu K, Sharma R, Gupta A** : Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. *Clin Transplant*; 15:173, 2001.

- Saltissi D, Morgan C, Rigby RJ, Westhuyzen J:** Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. *Am J Kidney Dis.*;39:283–90, 2002.
- Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H:** Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. *J Am Soc Nephrol*; 9:1482–1488,1998.
- Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B :** Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. *Nephrol Dial Transplant.* 12:1908 –1915, 1997.
- Santos AF, Keitel E, Bittar AE :** Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study. *Transplant Proc* 33:1194, 2001.
- Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinoso DJ, Wilson PW:** Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Circulation* 108:2154-2169, 2003.
- Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM:** Cholesterol and the risk of renal dysfunction in apparently healthy men. *J Am Soc Nephrol*;14:2084– 2091, 2003.
- Schmermund A, Baumgart D, Mohlenkamp S :** Natural history and topographic pattern pf progression of coronary calcification in symptomatic patients: An electron-beam CT study. *Arterioscler Thromb Vasc Biol* 21:421–426, 2001.
- Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME:** Prophylaxis of hemodialysis graft thrombosis with fish oil: Double-blind, randomized, prospective trial. *J Am Soc Nephrol* 13: 184–190, 2002.

- Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K:** Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. *Nephrol Dial Transplant* 15: 218–223, 2000.
- Semenkovich :** disorder of lipid metabolism. In : *Cecil medicine*, 23 ED., edited by lee goldman, Dennis Ausiello. Saunders Elsevier, Philadelphia. (217) 1546-1555., 2008 .
- Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X, Rubies-Prat J:** Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. *Kidney Int* 41: 1394–1399, 1992.
- Shepherd J, Kastelein JJ, Bittner V :** Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. *J Am Coll Cardiol*. 51:1448-1454, 2008.
- Shoji T, Nishizawa Y, Kawagishi T:** Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. *J Am Soc Nephrol* 9:1277-84, 1998.
- Siamopoulos KC, Gouva C, Katopodis KP, Tzallas C, Nikolopoulos P, Papavasiliou EC, Tselepis AD:** Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. *Am J Kidney Dis*;48:242-249, 2006
- Slatopolsky E, Finch J, Denda M, Hitter C, Zhong M, Dusso A, MacDonald PN, Brown AJ:** Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro, *J Clin Invest* 97: 2534-2540, 1996.
- Sniderman AD, Vu H, Cianflone K:** The effect of moderate hypertriglyceridemia on the relation of plasma total and LDL Apo B levels. *Atherosclerosis* 22: 1184–1191, 1991
- Snively CS, Gutierrez C :** Chronic Kidney Disease : Prevention and Treatment of Common Complications. *Am Fam Physician* 70:1921-30,2004.

- Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP:** Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* 432: 173–178, 2004.
- Staels, B, Dallongeville, J, Auwerx :** Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation* 98:2088,1998.
- Stampfer MJ, Krauss RM, Ma J:** A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. *JAMA*;276:882-88S, 1996.
- Steinmetz A, Barbaras R, Ghalim N, Clavey V, Fruchart JC, Ailhaud G:** Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. *J Biol Chem* 265: 7859–7863, 1990.
- Stenvinkel P, Heimbürger O, Paultre F, Diczfalussy U, Wang T, Berglund L, Jøgestrand T:** Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney Int* 55: 1899–1911, 1999.
- Stern RH, Yang BB, Horton M, Moore S, Abel RB, Olson SC:** Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. *J Clin Pharmacol.* 37:816–819, 1997.
- Sudhop T, Lutjohann D, Kodal A:** Inhibition of intestinal cholesterol absorption by ezetimibe in humans. *Circulation*; 106:1943, 2002.
- Svensson M, Schmidt EB, Jorgensen KA, Christensen JH:** N-3 Fatty Acids as Secondary Prevention Against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: a randomized, placebo-controlled intervention trial. *Clin J Am Soc Nephrol* 1: 780–6, 2006.
- Swaminathan S, Fonseca VA, Alam MG, Shah SV:** The role of iron in diabetes and its complications. *Diabetes Care.* 30:1926 –33, 2007.

- Tahvanainen E, Syvanne M, Frick MH :** Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Investigators. *J Clin Invest* 101:956, 1998.
- Takahashi S, Warabayasi Y, Nakai T, Sakai J, and Yamamoto T.** Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. *Proc Natl Acad Sci USA* 89: 9252–9256, 1992.
- Tamashiro M , Iseki K , Sunagawa O :** Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic haemodialysis. *Am J Kidney Dis* 38:64-9, 2001.
- Taylor AJ, Burke AP, O'Malley PG :** A comparison of the Framingham risk index, coronary artery calcification, and culprit plaque morphology in sudden cardiac death. *Circulation* 101:1243–1248, 2000.
- Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA:** Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A doubleblind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. *Circulation* 110: 3512–3517, 2004.
- Temel RE, Tang W, Ma Y :** Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. *J Clin Invest*; 117:1968, 2007.
- Tetta C, Biasioli S, Schiavon R:** An overview of haemodialysis and oxidant stress. *Blood Purif* 17:118-26, 1999.
- Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC:** Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. *Circulation* 112: 171–178, 2005.
- Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M:** Effect of pravastatin on cardiovascular events in people with chronic kidney disease. *Circulation* 110: 1557–1563, 2004.

- Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC;** for the Cholesterol and Recurrent Events (CARE) Trial Investigators: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. *J Am Soc Nephrol* 14: 1605–1613, 2003.
- Toshima S, Hasegawa A, Kurabayashi M :** Circulating oxidised low density lipoprotein levels. A biochemical risk marker for coronary heart disease. *Arterioscler Thromb Vasc Biol* 20: 2243–2247, 2000.
- Tsimihodimos V, Dounousi E, Siamopoulos K:** Dyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment. *Am J Nephrol*;28:958-973 ,2008.
- Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB:** Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. *N Engl J Med* 353: 46–57, 2005.
- Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G :** Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. *Transplant Proc*; 32:622, 2000.
- Turk TR, Voropaeva E, Kohnle M, Nurnberger J, Philipp T, Kribben A, Heemann U, Witzke O:** Ezetimibe treatment in hypercholesterolaemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. *Nephrol Dial Transplant* 23: 369–373, 2008.
- Tuzcu A, Bahceci M, Yilmaz E, Bahceci S, Tuzcu S:** The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. *Horm Metab Res*;36:716-720, 2004.
- Utermann G:** Lipoprotein(a). In: *The Metabolic & Molecular Bases of Inherited Disease*, 8th Ed., edited by Scriver CR, Beaudet AL, Sly WS, Valle D, New York, McGraw-Hill, pp 2753–2787, 2000.
- Vaccari CS, Hammoud RA, Nagamia SH :** Revisiting niacin: reviewing the evidence. *J Clin Lipidol*,1:248–255, 2007.

- Vanrenterghem Y, Lebranchu Y, Hene R :** Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. *Transplantation* 70: 1352–1359, 2000.
- Vaziri ND.** Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. *Am J Physiol Renal Physiol* 290: F262–F272, 2006.
- Vaziri ND, Liang K:** Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. *Kidney Int*; 61:1769-1775, 2002 .
- Vaziri ND, Liang K, Parks JS:** Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. *Am J Physiol Renal Physiol* ; 280:F823-F828, 2001.
- Vaziri ND, Sato T, and Liang K.** Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. *Kidney Int* 63: 1756– 1763, 2003.
- Vega GL, Toto RD, Grundy SM:** Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia . *Kidney Int*;47:579-586, 1995.
- Verhulst A, D’Haese PC, De Broe ME:** Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. *J Am Soc Nephrol.* 15:2249 –2257, 2004.
- Vincenti F, Schena FP, Paraskevas S :** A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. *Am J Transplant*; 8:307, 2008.
- Viron B, Donsimoni R, Michel C, al Khayat R, Mignon F:** Effect of recombinant human erythropoietin on nutritional status and plasma lipids in uremic patients. *Nephron*;60:249, 1992.
- Vu-Dac N, Schoonjans K, Kosykh V :** Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. *J Clin Invest*; 96:741,1995.

- Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J:** Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. *Nephrol Dial Transplant* 19: 2570–2575, 2004.
- Wanner C, Krane V, Marz W:** Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 353: 238–48, 2005.
- Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer P, Wieland H:** Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. *Ann intern Med* ; 119:263-269.1993.
- Warner MM, Guo J, Zhao Y:** The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. *Chin Med J (Engl)* 114: 275–279, 2001.
- Weiner DE , Sarnak MJ :** Managing Dyslipidemia in Chronic Kidney Disease. *J GEN INTERN MED* 19:1045–1052, 2004.
- Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ:** Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol* 15:1307-1315, 2004.
- Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ; Kidney Early Evaluation Program Investigators:** CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. *Am J Kidney Dis* 51(suppl 2):S13-S20, 2008.
- Wild SH, Fortmann SP, Marcovina SM:** A prospective casecontrol study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. *Arterioscler Thromb Vasc Biol* 17: 239–245, 1997.
- Wilder LB, Bachorik PS, Finney CA:** The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. *Am J Med* 99:374–377, 1995 153:257–258, 2000.

- Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB:** Prediction of coronary heart disease using risk factor categories. *Circulation* 97: 1837–1847, 1998.
- Wissing KM, inger P, Ghisdal L :** Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. *Transplantation*;82:771-778, 2006.
- Witztum JL, Steinberg D:** Role of oxidised low density lipoprotein in atherogenesis. *J Clin Invest* 88: 1785–1792, 1991.
- Wolfrum S, Jensen KS, Liao JK:** Endothelium dependent effects of statins. *Arterioscler Thromb Vasc Biol.* 23:729 –736, 2003.
- Yamada K, Fujimoto S, Tokura T:** Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. *Ren Fail* 27:361–5, 2005.
- Yukawa S, Hibino A, Maeda T, Mimura K, Yukawa A, Maeda A, Kishino M, Sonobe M, Mune M, Yamada Y:** Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in haemodialysis patients. *Nephrol Dial Transplant* 10[Suppl 3]: 1–3, 1995.
- Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM:** Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: A meta-analysis. *Am J Clin Nutr*,69;632-646,1999.
- Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C:** Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. *Kidney Int* 55: 648–658, 1999.